文献速递神经肿瘤

赖氨酸特异性组蛋白去甲基化酶1A(KDM1A/LSD1)抑制减弱DNA双链断裂修复并增强替莫唑胺在胶质母细胞瘤中的疗效

Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma.
PubMed 文献 · Neuro Oncol · 2023-01-01

该研究探讨KDM1A/LSD1在胶质母细胞瘤DNA双链断裂修复中的作用,以及KDM1A抑制剂与替莫唑胺联合应用的体外和体内效果。使用患者来源的胶质瘤干细胞,研究发现抑制KDM1A可减弱同源重组和非同源末端连接介导的DNA修复,增强替莫唑胺的疗效,并延长荷瘤小鼠的生存期。

要点

  • KDM1A在替莫唑胺治疗的胶质母细胞瘤患者中高表达。
  • 抑制KDM1A减弱同源重组和非同源末端连接介导的DNA双链断裂修复。
  • KDM1A抑制剂NCD38可跨越血脑屏障,与替莫唑胺联用显著延长荷瘤小鼠生存期。

核心结论

  • 研究结果提供证据表明,抑制KDM1A通过减弱DNA双链断裂修复途径使胶质母细胞瘤对替莫唑胺敏感。

研究设计与样本

  • 体外和体内研究,使用患者来源的胶质瘤干细胞,并采用原位小鼠模型。

主要发现

  • TCGA分析显示KDM1A在替莫唑胺治疗的胶质母细胞瘤患者中高表达。
  • 敲低、敲除或抑制KDM1A增强了替莫唑胺降低胶质瘤干细胞活力和自我更新的效果。
  • 药代动力学研究证实NCD38可轻易跨越血脑屏障。
  • CUT&Tag-seq显示KDM1A富集于DNA修复基因启动子,RNA-seq证实抑制KDM1A降低其表达。
  • 敲低或抑制KDM1A减弱同源重组和非同源末端连接介导的DNA修复能力,并增强替莫唑胺介导的DNA损伤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Efficient DNA repair in response to standard chemo and radiation therapies often contributes to glioblastoma (GBM) therapy resistance. Understanding the mechanisms of therapy resistance and identifying the drugs that enhance the therapeutic efficacy of standard therapies may extend the survival of GBM patients. In this study, we investigated the role of KDM1A/LSD1 in DNA double-strand break (DSB) repair and a combination of KDM1A inhibitor and temozolomide (TMZ) in vitro and in vivo using patient-derived glioma stem cells (GSCs). METHODS: Brain bioavailability of the KDM1A inhibitor (NCD38) was established using LS-MS/MS. The effect of a combination of KDM1A knockdown or inhibition with TMZ was studied using cell viability and self-renewal assays. Mechanistic studies were conducted using CUT&Tag-seq, RNA-seq, RT-qPCR, western blot, homologous recombination (HR) and non-homologous end joining (NHEJ) reporter, immunofluorescence, and comet assays. Orthotopic murine models were used to study efficacy in vivo. RESULTS: TCGA analysis showed KDM1A is highly expressed in TMZ-treated GBM patients. Knockdown or knockout or inhibition of KDM1A enhanced TMZ efficacy in reducing the viability and self-renewal of GSCs. Pharmacokinetic studies established that NCD38 readily crosses the blood-brain barrier. CUT&Tag-seq studies showed that KDM1A is enriched at the promoters of DNA repair genes and RNA-seq studies confirmed that KDM1A inhibition reduced their expression. Knockdown or inhibition of KDM1A attenuated HR and NHEJ-mediated DNA repair capacity and enhanced TMZ-mediated DNA damage. A combination of KDM1A knockdown or inhibition and TMZ treatment significantly enhanced the survival of tumor-bearing mice. CONCLUSIONS: Our results provide evidence that KDM1A inhibition sensitizes GBM to TMZ via attenuation of DNA DSB repair pathways.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Alejo S, Palacios BE, Venkata PP, et al. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023. PMID: 36652263. doi:10.1093/neuonc/noad018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。